最新ニュース BioLine Rx (NASDAQ:BLRX) 株価情報

BioLine Rx

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLineRx Ltd. - American Depositary Shares

BioLine Rx Ltd

<h3>Gainers</h3>
<ul>
<li>Regional Health Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RHE#AMEX">RHE</a>) stock increased by 183.9% to $4.4 during Monday's pre-market session. The market value of their outstanding shares is at $8.2 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) shares moved upwards by 38.32% to $1.01. The market value of their outstanding shares is at $22.2 million. </li>
<li>Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) shares increased by 29.9% to $2.78. The market value of their outstanding shares is at $47.0 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock moved upwards by 23.11% to $1.14. The company's market cap stands at $180.9 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares moved upwards by 21.38% to $2.1. The market value of their outstanding shares is at $24.1 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 18.86% to $0.15. The market value of their outstanding shares is at $8.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) stock declined by 71.6% to $0.16 during Monday's pre-market session. The market value of their outstanding shares is at $6.4 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock fell 37.41% to $0.18. The market value of their outstanding shares is at $2.9 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock fell 29.0% to $0.19. The market value of their outstanding shares is at $16.3 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock fell 24.13% to $0.23. The company's market cap stands at $2.3 million. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) shares fell 18.31% to $1.45. The company's market cap stands at $8.9 million. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) stock decreased by 17.93% to $0.45. The market value of their outstanding shares is at $2.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACON

AEON

AYTU

BLRX

CNSP

EKSO

GCTK

MBOT

RENB

SCPX

12 Health Care Stocks Moving In Monday's Pre-Market Session

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping more than 200 points on Monday.
The Dow traded up 0.08% to 42,765.84 while the NASDAQ gained 1.05% to 19,828.63. The S&amp;P 500 also rose, gaining, 0.59% to 5,976.38.
Check This Out: <a href="https://www.benzinga.com/25/01/42810054/this-analyst-with-85-accuracy-rate-sees-around-16-downside-in-tesla-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 85% Accuracy Rate Sees Around 16% Downside In Tesla &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Information technology shares jumped by 2.1% on Monday.
In trading on Monday, utilities shares fell by 0.6%.
Top Headline
The S&amp;P Global services PMI was revised downward to 56.8 in December compared to a preliminary reading of 58.5, and versus a reading of 56.1 in November.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Regional Health Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHE#NYSE">RHE</a>) shares shot up 131% to $3.5824. Regional Health announced plans to merge with SunLink in a $10 million preferred stock deal.</li>
<li>Shares of SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>)got a boost, surging 108% to $1.10 after announcing the publication of a European patent application for binge behavior.</li>
<li>fuboTV Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NASDAQ">FUBO</a>) shares were also up, gaining 235% to $4.83 after the company announced it entered into a definitive agreement for Disney to combine its Hulu with Fubo to form a virtual MVPD company.</li>
</ul>
Equities Trading DOWN
<ul>
<li>AEON Biopharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEON#NYSE">AEON</a>) shares dropped 67% to $0.1884 after the company announced the pricing of approximately $20.0 million underwritten public offering.</li>
<li>Shares of BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) were down 42% to $0.1586 after the company reported a $10 million registered direct offering.</li>
<li>Blue Hat Interactive Entertainment Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) was down, falling 41% to $0.0868 after the company reported the pricing of $4.4 million registered direct offering.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $73.92 while gold traded down 0.2% at $2,648.90.
Silver traded up 1.9% to $30.640 on Monday, while copper rose 2.4% to $4.1695.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.95%, Germany's DAX 40 gained 1.56% and France's CAC 40 climbed 2.24%. Spain's IBEX 35 Index rose 1.34%, while London's FTSE 100 rose 0.31%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 falling 1.47%, China's Shanghai Composite Index falling 0.14%, Hong Kong's Hang Seng Index declining 0.36% and India's BSE Sensex falling 1.59%.
Economics
The S&amp;P Global services PMI was revised downward to 56.8 in December compared to a preliminary reading of 58.5, and versus a reading of 56.1 in November.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42809598/progress-software-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Progress Software Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

BHAT

FUBO

SPRC

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

U.S. stocks traded higher midway through trading, with the S&amp;P 500 jumping more than 1% on Monday.
The Dow traded up 0.51% to 42,949.22 while the NASDAQ gained 1.78% to 19,970.13. The S&amp;P 500 also rose, gaining, 1.09% to 6,007.42.
Check This Out: <a href="https://www.benzinga.com/25/01/42810054/this-analyst-with-85-accuracy-rate-sees-around-16-downside-in-tesla-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 85% Accuracy Rate Sees Around 16% Downside In Tesla &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Information technology shares jumped by 2.3% on Friday.
In trading on Friday, utilities shares fell by 1.2%.
Top Headline
The S&amp;P Global services PMI was revised downward to 56.8 in December compared to a preliminary reading of 58.5, and versus a reading of 56.1 in November.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Regional Health Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHE#NYSE">RHE</a>) shares shot up 171% to $4.2050. Regional Health announced plans to merge with SunLink in a $10 million preferred stock deal.</li>
<li>Shares of SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>)got a boost, surging 160% to $1.3701 after announcing the publication of a European patent application for binge behavior.</li>
<li>fuboTV Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NASDAQ">FUBO</a>) shares were also up, gaining 153% to $3.6610 after the company announced it entered into a definitive agreement for Disney to combine its Hulu with Fubo to form a virtual MVPD company.</li>
</ul>
Equities Trading DOWN
<ul>
<li>AEON Biopharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEON#NYSE">AEON</a>) shares dropped 67% to $0.1894 after the company announced the pricing of approximately $20.0 million underwritten public offering.</li>
<li>Shares of BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) were down 39% to $0.1659 after the company reported a $10 million registered direct offering.</li>
<li>Blue Hat Interactive Entertainment Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) was down, falling 39% to $0.0900 after the company reported the pricing of $4.4 million registered direct offering.</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $74.75 while gold traded down 0.1% at $2,651.60.
Silver traded up 2.2% to $30.715 on Monday, while copper rose 3.1% to $4.1980.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.54%, Germany's DAX 40 gained 1.05% and France's CAC 40 climbed 1.68%. Spain's IBEX 35 Index rose 0.82%, while London's FTSE 100 fell 0.06%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 falling 1.47%, China's Shanghai Composite Index falling 0.14%, Hong Kong's Hang Seng Index declining 0.36% and India's BSE Sensex falling 1.59%.
Economics
The S&amp;P Global services PMI was revised downward to 56.8 in December compared to a preliminary reading of 58.5, and versus a reading of 56.1 in November.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42809598/progress-software-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Progress Software Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

S&P Jumps 1%; Regional Health Properties Shares Spike Higher

WIIM

BioLineRx shares are trading lower after the company announced a $10 million registered direct offering.

U.S. stocks traded higher this morning, with the Dow Jones index surging more than 200 points on Monday.
Following the market opening Monday, the Dow traded up 0.58% to 42,979.82 while the NASDAQ gained 1.45% to 19,905.93. The S&amp;P 500 also rose, gaining, 1.03% to 6,003.89.
Check This Out: <a href="https://www.benzinga.com/25/01/42810054/this-analyst-with-85-accuracy-rate-sees-around-16-downside-in-tesla-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 85% Accuracy Rate Sees Around 16% Downside In Tesla &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Information technology shares jumped by 2% on Monday.
In trading on Monday, utilities shares fell by 0.9%.
Top Headline
The S&amp;P Global services PMI was revised downward to 56.8 in December compared to a preliminary reading of 58.5, and versus a reading of 56.1 in November.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Regional Health Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHE#NYSE">RHE</a>) shares shot up 220% to $4.9164. Regional Health announced plans to merge with SunLink in a $10 million preferred stock deal.</li>
<li>Shares of SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>)got a boost, surging 157% to $1.36 after announcing the publication of a European patent application for binge behavior.</li>
<li>fuboTV Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NASDAQ">FUBO</a>) shares were also up, gaining 133% to $3.36 after the company announced it entered into a definitive agreement for Disney to combine its Hulu with Fubo to form a virtual MVPD company.</li>
</ul>
Equities Trading DOWN
<ul>
<li>AEON Biopharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEON#NYSE">AEON</a>) shares dropped 69% to $0.1744 after the company announced the pricing of approximately $20.0 million underwritten public offering.</li>
<li>Shares of BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) were down 43% to $0.1543 after the company reported a $10 million registered direct offering.</li>
<li>Blue Hat Interactive Entertainment Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) was down, falling 42% to $0.0858 after the company reported the pricing of $4.4 million registered direct offering.</li>
</ul>
Commodities In commodity news, oil traded up 1.2% to $74.85 while gold traded down 0.4% at $2,643.60.
Silver traded up 1.7% to $30.565 on Monday, while copper rose 2.8% to $4.1855.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.5%, Germany's DAX 40 gained 1% and France's CAC 40 climbed 1.5%. Spain's IBEX 35 Index rose 0.7%, while London's FTSE 100 rose 0.1%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 falling 1.47%, China's Shanghai Composite Index falling 0.14%, Hong Kong's Hang Seng Index declining 0.36% and India's BSE Sensex falling 1.59%.
Economics
The S&amp;P Global services PMI was revised downward to 56.8 in December compared to a preliminary reading of 58.5, and versus a reading of 56.1 in November.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42809598/progress-software-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Progress Software Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

US Stocks Open Higher; Dow Jumps Over 200 Points

BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) (TASE: BLRX)&nbsp;("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements for the purchase of an aggregate of 50,000,000&nbsp;of the Company's American Depositary Shares (ADSs) (or ADS equivalents) and accompanying warrants to purchase up to an aggregate of 50,000,000 ADSs, at a purchase price of $0.20 per ADS (or per ADS equivalent) and accompanying warrant in a registered direct offering. The warrants will have an exercise price of $0.20 per share, will be exercisable immediately upon issuance, and will expire five years from the initial exercise date.&nbsp; Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx. The closing of the offering is expected to occur on or about January 7, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for research and development activities, the expansion of the Company's pipeline of potential drug candidates, and working capital and general corporate purposes.

Offerings

BioLineRx Announces $10M Registered Direct Offering Of 50M American Depositary Shares And Accompanying Warrants To Purchase Up To An Aggregate Of 50M ADSs, At A Purchase Price Of $0.20 Per ADS

Shares of Check-Cap Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEK#NASDAQ">CHEK</a>) rose sharply in today's pre-market trading after the company announced it was granted European Patent Number EP4087488 titled &#8220;RADIATION CAPSULE FOR BOWEL DISEASE IMAGING <a href="https://www.benzinga.com/quote/CHEK">AND LOCALIZE DRUG DELIVERY&#8221;.</a>
Check-Cap shares jumped 52.2% to $1.75 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) gained 151.2% to $0.4760 in pre-market trading after gaining around 7% on Thursday.</li>
<li>BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) gained 91.4% to $0.4891 in pre-market trading after surging 20% on Thursday.</li>
<li>mF International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>) rose 80% to $1.30 in pre-market trading after gaining around 8% on Thursday.</li>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) rose 48.5% to $0.8776 in pre-market trading after climbing around 5% on Thursday.</li>
<li>Nine Energy Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) gained 30.9% to $1.61 in pre-market trading following a 10% surge on Thursday.</li>
<li>Inspire Veterinary Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) gained 27.6% to $0.2630 in pre-market trading after gaining 8% on Thursday.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) gained 27.3% to $2.42 in pre-market trading after dipping 13% on Thursday.</li>
<li>Garrett Motion Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NYSE">GTX</a>) rose 11.3% to $9.92 in pre-market trading.</li>
<li>Meritage Homes Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) gained 10.5% to $84.00 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Coeptis Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) fell 30.4% to $4.11 in pre-market trading after jumping 7% on Thursday.</li>
<li>T Stamp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) declined 19.8% to $0.5470 in pre-market trading after dipping 23% on Thursday. The company announced it will implement a 1-for-15 reverse stock split.</li>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) fell 18.3% to $0.5300 in pre-market trading.</li>
<li>Reservoir Media, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSVR#NASDAQ">RSVR</a>) shares dipped 18% to $7.00 in pre-market trading after falling over 5% on Thursday.</li>
<li>Creative Media &amp; Community Trust Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) shares fell 17.9% to $0.1716 in pre-market trading. Creative Media announced approval for a 1-for-10 reverse stock split.</li>
<li>IT Tech Packaging, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITP#NYSE">ITP</a>) fell 14.9% to $0.5700 in today's pre-market trading after jumping more than 11% on Thursday.</li>
<li>Ark Restaurants Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKR#NASDAQ">ARKR</a>) fell 13.7% to $11.01 in pre-market trading after gaining 16% on Thursday.</li>
<li>Tejon Ranch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRC#NYSE">TRC</a>) shares fell 11.4% to $14.01 in pre-market trading.</li>
<li>Aura Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) dipped 11.1% to $0.75 in pre-market trading.</li>
<li>Lincoln Educational Services Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) shares tumbled 7.7% to $14.10 in pre-market trading after falling over 3% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Acuity Brands Stock Ahead Of Q1 Earnings</a></li>
</ul>

ARKR

AURA

CHEK

CMCT

COEP

IDAI

LINC

MGOL

NINE

RSVR

Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) with a Buy and lowers the price target from $21 to $9.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on BioLine Rx, Lowers Price Target to $9

BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) reported quarterly losses of $(0.00) per share which beat the analyst consensus estimate of $(0.05) by 98 percent. The company reported quarterly sales of $4.94 million which missed the analyst consensus estimate of $5.29 million by 6.57 percent.

Earnings

BioLine Rx Q3 2024 GAAP EPS $(0.00) Beats $(0.05) Estimate, Sales $4.94M Miss $5.29M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.00 million. 
• BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report quarterly loss at $0.10 per share on revenue of $4.12 million. 
• Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) is estimated to report earnings for its second quarter. 
• Super Hi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDL#NASDAQ">HDL</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $227.49 million. 
• Diana Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $68.00 million. 
• Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) is expected to report quarterly earnings at $0.47 per share on revenue of $1.58 billion. 
• Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is expected to report quarterly loss at $0.16 per share on revenue of $5.95 million. 
<h3>Companies Reporting After The Bell</h3>
• BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $776.51 million. 
• Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) is estimated to report quarterly earnings at $1.40 per share on revenue of $1.67 billion. 
• Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) is likely to report quarterly loss at $0.22 per share on revenue of $706.77 million. 
• Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) is projected to report quarterly loss at $0.20 per share on revenue of $707.30 million. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its third quarter. 
• Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) is projected to report quarterly loss at $0.02 per share on revenue of $69.82 million. 
• Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $404.09 million. 
• Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $232.90 million. 
• Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $40.00 million. 
• Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $1.31 billion. 
• Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is expected to report quarterly earnings at $1.31 per share on revenue of $1.16 billion. 
• Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is likely to report quarterly earnings at $1.25 per share on revenue of $812.95 million. 
• Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) is expected to report quarterly earnings at $0.67 per share on revenue of $324.70 million. 
• Grupo Supervielle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $199.08 million. 
• New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $407.00 million. 
• Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) is expected to report quarterly earnings at $0.22 per share on revenue of $36.14 million. 
• PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $48.95 million. 
• Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is likely to report quarterly loss at $1.16 per share on revenue of $17.93 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAR

BBWI

BLBD

CENT

CENTA

CRGO

ENTA

FLNC

HSAI

LESL

PFLT

PNNT

SMTC

SUPV

TBBB

UXIN

Earnings Scheduled For November 25, 2024

BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is preparing to release its quarterly earnings on Monday, 2024-11-25. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect BioLine Rx to report an earnings per share (EPS) of $-0.10.
Anticipation surrounds BioLine Rx's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.14, leading to a 8.88% increase in the share price on the subsequent day.
Here's a look at BioLine Rx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.14</td>
<td>-0.29</td>
<td>-0.22</td>
<td>-0.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0</td>
<td>-0.01</td>
<td>-0.15</td>
<td>-0.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>-4.0%</td>
<td>8.0%</td>
<td>-11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732284187_0.png" alt="eps graph" />
<h3>BioLine Rx Share Price Analysis</h3>
Shares of BioLine Rx were trading at $0.32325 as of November 21. Over the last 52-week period, shares are down 77.86%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/BLRX/earnings">To track all earnings releases for BioLine Rx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For BioLine Rx

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares moved upwards by 71.4% to $1.68 during Thursday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) stock rose 55.36% to $0.14. The market value of their outstanding shares is at $14.7 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares rose 28.96% to $19.5. The market value of their outstanding shares is at $137.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock rose 27.46% to $75.55. The company's market cap stands at $548.9 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock increased by 16.88% to $4.5. The market value of their outstanding shares is at $65.3 million. </li>
<li>DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) stock increased by 14.1% to $0.89. The market value of their outstanding shares is at $30.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) stock fell 43.5% to $2.16 during Thursday's pre-market session. The company's market cap stands at $128.3 million. </li>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) shares declined by 27.23% to $4.49. The market value of their outstanding shares is at $303.4 million. </li>
<li>Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) stock decreased by 25.52% to $11.85. The company's market cap stands at $921.5 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock decreased by 22.42% to $0.42. The company's market cap stands at $33.8 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock declined by 20.0% to $0.27. The market value of their outstanding shares is at $3.8 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) stock fell 11.06% to $13.36. The market value of their outstanding shares is at $84.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASMB

BDRX

CATX

CDTX

DRIO

KURA

PYXS

SLXN

SMLR

WORX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<ul>
<li>Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous Transplantation In Patients With Multiple Myeloma.</li>
<li>BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23%.</li>
<li>BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC.</li>
<li>BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion.</li>
<li>Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases –</li>
</ul>

Biotech

Health Care

Contracts

General

BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) with a Buy and maintains $21 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target

- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle -&nbsp;
- Data from proof-of-concept&nbsp;study shows that motixafortide was safe and well tolerated -
- Oral presentation at ASH 2024 on Saturday, December 7, 2024 in San Diego, California -
TEL AVIV, Israel and WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- <a href="https://biolinerx.com/">BioLineRx&nbsp;Ltd.</a>&nbsp;(NASDAQ:&nbsp;BLRX) (TASE:&nbsp;BLRX),&nbsp;a commercial&nbsp;stage&nbsp;biopharmaceutical&nbsp;company pursuing&nbsp;life-changing&nbsp;therapies&nbsp;in&nbsp;oncology&nbsp;and rare diseases,&nbsp;today&nbsp;announced&nbsp;that an abstract including the initial results from a Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD) was accepted for oral presentation&nbsp;at the 66th&nbsp;American Society of Hematology (ASH) Annual Meeting &amp; Exposition taking place&nbsp;December 7-10, 2024 in San Diego, California. The proof-of-concept study, conducted in collaboration with Washington University School of Medicine in St. Louis, is exploring alternative HSC mobilization strategies that could significantly improve the treatment journey of patients with sickle cell disease seeking gene therapy. &nbsp;&nbsp;

BioLineRx Announces Oral Presentation On Data From Phase 1 Clinical Trial Evaluating Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapies In Sickle Cell Disease At ASH 2024

BioLineRx Announces USPTO Allowance Of New Composition Of Matter Patent Covering Composition Of Motixafortide

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock rose 89.7% to $0.72 during Friday's after-market session. The market value of their outstanding shares is at $122.8 million. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock rose 5.75% to $0.69. The market value of their outstanding shares is at $61.2 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock rose 5.4% to $0.39. The company's market cap stands at $36.7 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares increased by 5.02% to $0.26. The company's market cap stands at $14.4 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares rose 4.99% to $0.54. The company's market cap stands at $2.3 million. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) shares moved upwards by 4.98% to $12.84. The market value of their outstanding shares is at $771.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock fell 8.4% to $0.95 during Friday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 7.79% to $3.79. The market value of their outstanding shares is at $5.0 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares declined by 7.56% to $0.72. The market value of their outstanding shares is at $7.6 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 7.14% to $0.91. The company's market cap stands at $9.2 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares fell 6.88% to $0.45. The company's market cap stands at $36.2 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock fell 6.36% to $0.17. The company's market cap stands at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

ALLK

CARA

DWTX

IMNM

NIVF

PTIX

TVGN

UNCY

12 Health Care Stocks Moving In Friday's After-Market Session

Shares of Arcadium Lithium plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NASDAQ">ALTM</a>) rose sharply in today's pre-market trading after the company confirmed non-binding acquisition <a href="https://www.benzinga.com/quote/ALTM/analyst-ratings">approach by Rio Tinto</a>.
Arcadium Lithium shares jumped 27.8% to $3.94 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) rose 54.5% to $0.1735 in pre-market trading after dipping 17% on Friday.</li>
<li>TDH Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETZ#NASDAQ">PETZ</a>) rose 36.2% to $1.84 in pre-market trading after jumping 13% on Friday.</li>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) gained 16.8% to $1.95 in pre-market trading after declining 5% on Friday.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) shares gained 13.3% to $14.04 in pre-market trading after jumping around 35% on Friday.</li>
<li>Garden Stage Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIW#NASDAQ">GSIW</a>) shares rose 13.1% to $2.16 in pre-market trading after gaining around 3% on Friday.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) shares surged 12.6% to $1.25 in pre-market trading after dipping 17% on Friday.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) shares jumped 11% to $4.13 in pre-market trading after gaining 17% on Friday.</li>
<li>The Duckhorn Portfolio, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAPA#NYSE">NAPA</a>) shares gained 11% to $6.00 in pre-market trading ahead of quarterly earnings.</li>
<li>BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) gained 9.5% to $0.5035 in pre-market trading after dipping around 12% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Trevena, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares dipped 39% to $2.81 in pre-market trading after the company announced it received a Nasdaq delisting notification.</li>
<li>Beneficient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) fell 22.2% to $1.47 in today's pre-market trading. Beneficient shares jumped around 59% on Friday after the company announced its subsidiary, Beneficient Company Holdings, consummated a previously announced transaction pursuant to which approximately $126 million of its preferred equity was redesignated as non-redeemable.</li>
<li>Mynaric AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) shares fell 18.7% to $1.26 in pre-market trading after gaining 4% on Friday.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) fell 18.4% to $1.64 in pre-market trading after declining 21% on Friday.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) declined 17.2% to $0.2330 in pre-market trading after dipping around 24% on Friday.</li>
<li>Vicinity Motor Corp.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) shares declined 17.3% to $0.1448 in pre-market trading after gaining around 23% on Friday.</li>
<li>DigiAsia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) fell 15.8% to $1.75 in pre-market trading after declining 8% on Friday.</li>
<li>Chanson International Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) shares fell 15.8% to $12.47 in pre-market trading after jumping 387% on Friday.</li>
<li>Stepan Company  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCL#NYSE">SCL</a>) shares fell 6.5% to $72.29.</li>
<li>Fortuna Mining Corp. NYSE: FSM) shares declined 5.3% to $4.62 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41196046/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yiel">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

ALTM

BENF

CETX

CHSN

CTNT

EFSH

FAAS

GSIW

LGMK

MYNA

NAPA

PETZ

TIGR

TRVN

Why Arcadium Lithium Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket

Patient&nbsp;survey&nbsp;currently&nbsp;underway in&nbsp;partnership&nbsp;with&nbsp;the&nbsp;HealthTree Foundation; data expected in Q1 2025
TEL AVIV, Israel and WALTHAM, Mass., Sept. 17, 2024 /PRNewswire/ -- <a href="https://biolinerx.com/">BioLineRx&nbsp;Ltd.</a>&nbsp;(NASDAQ:&nbsp;BLRX) (TASE:&nbsp;BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the launch of <a href="https://www.mobilizationmatters.com/">Mobilization&nbsp;Matters</a>,&nbsp;a&nbsp;digital&nbsp;resource for&nbsp;people with multiple myeloma who are preparing for stem cell collection for an autologous stem cell transplant. Launched on Apheresis Awareness Day, this platform offers patient stories, educational resources, and more to support those undergoing this critical phase of treatment.

BioLineRx Launches 'Mobilization Matters', A Digital Resource For People With Multiple Myeloma Preparing For Stem Cell Collection; Patient Survey Currently Underway In Partnership With The HealthTree Foundation; Data Expected In Q1 2025

Jones Trading analyst Justin Walsh initiates coverage on BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) with a Buy rating and announces Price Target of $2.

Initiation

Jones Trading Initiates Coverage On BioLine Rx with Buy Rating, Announces Price Target of $2

Bioline RX Ltd Sponsored ADR (BLRX) has released an update. BioLineRx Ltd has entered a strategic license agreement with Ayrmid Ltd. for its APHEXD...

BioLineRx Secures Key Deals to Boost Shareholder Value

Reports Q3 revenue $4.94M. No revenue reported in Q3 of last year. "The license agreement for APHEXDA that we announced last week was made possible...

BioLineRx reports Q3 EPS 0c vs. (2c) last year

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

H.C. Wainwright lowered the firm's price target on BioLineRx (BLRX) to $9 from $21 and keeps a Buy rating on the shares after the company announced...

BioLineRx price target lowered to $9 from $21 at H.C. Wainwright

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has released its Q3 earnings. Here is a breakdown of the information Bioline RX Ltd Sponsored ADR presente...

BioLineRx Reports Strategic Moves in Q3 2024

JonesTrading analyst Justin Walsh reiterated a Buy rating on Bioline RX Ltd Sponsored ADR (BLRX – Research Report) today. The company's shares open...

JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX)

BioLineRx (BLRX) announced that it has entered into definitive agreements for the purchase of an aggregate of 50M of the company's American Deposit...

BioLineRx announces $10M registered direct offering

The latest update is out from Bioline RX Ltd Sponsored ADR ( ($BLRX) ). BioLineRx Ltd. has announced a $10 million registered direct offering invol...

BioLineRx Announces $10 Million Direct Offering to Fuel Growth

BioLineRx announces $10M registered direct offering; shares tumble

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has issued an update. BiolineRx Ltd., an Israeli company, has announced a registered direct offering invol...

BiolineRx Announces Major Direct Offering to Bolster Operations

Press Releases

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Small Cap

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Management

Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

BioLineRx Announces $10 Million Registered Direct Offering

AIM ImmunoTech

Ainos

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Ensysce Biosciences

Eterna Therapeutics

HCW Biologics

Imunon

Immuron Limited - American Depositary Shares

Immuron

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

MEI Pharma

Mainz Biomed

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

BiomX

PharmaCyte Biotech

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Spruce Biosciences

Synlogic

Turnstone Biologics

Comments

BioLine Rx

ニュース

最新ニュース BioLine Rx (NASDAQ:BLRX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル